stockportfolio.pro
DexCom, Inc. (DXCM)
Healthcare · Medical Devices · NasdaqGS
DexCom, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $573.30M | $718.50M | $1.03B | $1.48B | $1.93B | $2.45B | $2.91B | $3.62B | $4.03B | $4.66B |
| Gross profit | $378.40M | $492.10M | $663.90M | $931.50M | $1.28B | $1.68B | $1.88B | $2.29B | $2.44B | $2.80B |
| Net income | $-65.60M | $-50.20M | $-127.10M | $101.10M | $549.70M | $216.90M | $341.20M | $541.50M | $576.20M | $836.30M |
| Net margin | -11.4% | -7.0% | -12.3% | 6.8% | 28.5% | 8.9% | 11.7% | 14.9% | 14.3% | 17.9% |
Source: DexCom, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
What growth is priced into DXCM stock?
At today's market cap of $30.17B, DexCom, Inc. is priced for free-cash-flow growth of about 12.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.08B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 31.2%/yr over the last five fiscal years and revenue 19.3%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 17 years of DexCom, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track DXCM in your portfolio →
DexCom, Inc. financial history by metric
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
DexCom, Inc. — frequently asked questions
What is DexCom, Inc.'s revenue?
DexCom, Inc. (DXCM) reported revenue of $4.66B for fiscal year 2025, up 15.6% from the prior year, according to its SEC filings.
Is DexCom, Inc. profitable?
Yes. DXCM earned net income of $836.30M in fiscal 2025, a net margin of 17.9%.
What is DXCM's P/E ratio?
DexCom, Inc. trades at a price-to-earnings ratio of about 32.9 based on the latest data in our nightly-refreshed cache.
How fast is DexCom, Inc. growing?
DXCM's revenue grew at roughly 19.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does DexCom, Inc. have?
As of fiscal year 2025, DXCM carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is DexCom, Inc.'s gross margin?
DXCM's gross margin was 60.1% in fiscal 2025 — gross profit of $2.80B on revenue of $4.66B.
What is DexCom, Inc.'s market cap?
DexCom, Inc. (DXCM) has a market capitalization of about $30.17B, based on the latest data in our nightly-refreshed cache.
When does DexCom, Inc.'s fiscal year end?
DXCM's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into DXCM stock?
At today's market cap of $30.17B, DexCom, Inc. is priced for free-cash-flow growth of about 12.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.08B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 31.2%/yr over the last five fiscal years and revenue 19.3%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from DexCom, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.